



AJCN Publication Garnering Tremendous Interest

First-of-kind analysis reveals celiac patients consume significant gluten

ImmunogenX is pleased to announce the publication of a manuscript that provides the first analytical determination of the quantity of gluten that celiac disease (CD) patients consume while practicing a gluten-free diet (GFD).

“Determination of Gluten Consumption in Celiac Disease Patients on a Gluten-Free Diet”
American Journal of Clinical Nutrition. 2018;107:201-207, J.A. Syage, C.P. Kelly, M.A. Dickason,
A.C. Ramirez, F. Leon, R. Dominguez, J.A. Sealey-Voyksner

It is well recognized that adherence to a GFD is impractical and nearly impossible to achieve. However, until this analysis, involving the measurement of gluten in urine and stool samples of CD patients, there was little basis for estimating the amount of gluten that is inadvertently consumed by patients on a GFD. These new results indicate that it is not unusual for CD patients to consume hundreds of milligrams of gluten on a given day where less than 50 mg/day is considered a safe level. These results suggest significant health ramifications for CD patients and demonstrate that a GFD alone is an inadequate treatment option. Clearly therapeutic treatments are needed to supplement a GFD.

The significance of this work is evidenced by the article being chosen as the “Editor’s Choice” for this issue of AJCN and being reported on Reuters Health News, NPR The Salt, as well as featured by Beyond Celiac, Celiac Disease Foundation and the Gluten-Free Watchdog, all advocacy groups for CD.

As noted by one of the peer journal reviewers, “Overall I think this is an extremely well written paper on a topic that is absolutely necessary to begin to investigate given the direction of the field of celiac disease.”

Peter H.R. Green, MD, the Director of the Celiac Disease Center at Columbia University comments; “The ImmunogenX team has made a significant contribution that may well achieve landmark status. Understanding the distribution of gluten consumption in a broad population of celiac disease patients adhering to a gluten-free diet is crucial for providing better treatment options.”

ImmunogenX continues to establish its research excellence in addition to its therapeutic leadership in the field of celiac disease.

About ImmunogenX

ImmunogenX (a subsidiary of Immunogenics LLC) is a clinical-stage biotherapeutics company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company is developing Latiglutenase for celiac disease therapy. ImmunogenX is also developing a minimally-invasive diagnostic tool for celiac disease management (CypCel[™]) based on a clinically relevant metabolic marker compound that can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment. For food safety, ImmunogenX is pioneering advanced mass spectrometry methods to identify and measure physiologically relevant gluten peptide sequences found in wheat, barley, and rye.

www.immunogenx.com

For further information please contact

Matthew Dickason, COO
949 679-0900
mdickason@immunogenx.com